Clinical trials: Amyloidosis Cardiac
Amyloidosis, Paraproteinemias
Prospective Identification of Cardiac Amyloidosis by Cardiac Magnetic Resonance Imaging
Cardiac amyloidosis describes a process by which abnormally folded proteins infiltrate the heart tissue. Given the insidious nature of this disease process, diagnosis is often too late for a meaningful intervention.
- Conditions
- Amyloidosis, Paraproteinemias, Cardiomyopathies
- Trial name
- PICA-CMR (NCT02462213)
- Testing
- Amyloidosis, Cardiac Amyloidosis
- Where
- United States
- Sponsor
- University of Cincinnati
Cardiac Amyloidosis
Imaging Cardiac Amyloidosis: A Pilot Study Using F-18 Florbetapir Positron Emission Tomography
The primary aim of this pilot study is to determine whether amyloid deposits in the heart can be measured non-invasively by F-18 florbetapir (Trade Name: Amyvid) positron emission tomography (PET) in 30 individuals with…
- Trial name
- NCT01683825
- Testing
- F-18 florbetapir PET
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Cardiac Amyloidosis
Cardiac Amyloidosis : Diagnostic Using Red Flag Signals
Cardiac amyloidosis is an increasingly contributor of degenerative cardiac diseases. However, its frequency remains underestimated, and diagnosis is often realized at late stages of the disease.
- Trial name
- TEAM Red Flags (NCT04459169)
- Testing
- diagnostic algorithm
- Where
- 3 sites in Guadeloupe, Martinique
- Volunteers
- 424 people
- Sponsor
- University Hospital Center of Martinique
Cardiomyopathy, Ischemic Heart Disease
A Study Of Deep Learning For Echo Analysis, Tracking, And Evaluation
The purpose of this study is to deploy and evaluate informational AI-Echo algorithms that assist echo clinicians in interpreting core echocardiographic parameters (e.g., LV/RV size and function, valvular disease severity) and…
- Conditions
- Cardiomyopathy, Ischemic Heart Disease, Cardiac Amyloidosis
- Trial name
- NCT07308704
- Testing
- Transthoracic Echocardiography (TTE)
- Where
- United States
- Volunteers
- 10,040,000 people
- Sponsor
- Mayo Clinic
AL Amyloidosis
Novel Imaging Tools in Newly-diagnosed Patients With Cardiac AL Amyloidosis
This will be a systematic, combined, prospective assessment of the novel echographic, CMR, and PET imaging tools in newly-diagnosed patients with cardiac AL amyloidosis at baseline and after treatment.
- Trial name
- NCT04392960
- Testing
- [18F]Florbetaben
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Atherosclerosis
Aliskiren Effect on Aortic Plaque Progression
This study is being done to assess the effectiveness of short term (~9 months) Aliskiren/Placebo therapy to slow down the progression of atherosclerotic disease in thoracic and abdominal aorta.
- Trial name
- ALPINE (NCT01417104)
- Testing
- Aliskiren
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- Ohio State University
Cardiac Failure, Coronary Artery Disease
Evaluation of MyoStrain™ in Clinical Practice
Evaluate MyoStrain cardiac MRI pulse sequence in Clinical practice
- Conditions
- Cardiac Failure, Coronary Artery Disease, Sarcoidosis, Amyloidosis
- Trial name
- NCT03825224
- Testing
- Diagnostic Test: Myostrain
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Kansas Medical Center
Cardiac Amyloidosis
MECKI-Amyloidosis: Assessment of the Exercise Capacity and Prognosis of Patients with Cardiac Amyloidosis
This study aims to advance the understanding of cardiac amyloidosis, its effects on exercise capacity, and its prognostic implications.
- Trial name
- MECKI-AMI (NCT06799273)
- Where
- Italy
- Volunteers
- 1,400 people
- Sponsor
- Centro Cardiologico Monzino
HCM - Hypertrophic Cardiomyopathy, Anderson Fabry Disease
Myocardial Perfusion CMR for Differentiating and Characterizing Hypertrophic Cardiomyopathy Phenotypes
This observational study aims to evaluate myocardial perfusion abnormalities using quantitative and qualitative cardiac magnetic resonance (CMR) perfusion imaging in patients with hypertrophic cardiomyopathy (HCM) phenotypes…
- Conditions
- HCM - Hypertrophic Cardiomyopathy, Anderson Fabry Disease, Cardiac Magnetic Resonance Imaging, Amyloid Cardiomyopathy
- Trial name
- MyoPerf-HCM (NCT07382128)
- Where
- Italy
- Volunteers
- 250 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Acute Coronary Artery Syndrome
Plaque Regression and Progenitor Cell Mobilization With Intensive Lipid Elimination Regimen (PREMIER), Phase II
The purpose of this randomized, multi-site, clinical trial is to determine whether intensive therapy consisting of cholesterol-lowering statin drugs plus apheresis to cleanse the blood of low-density lipoprotein (LDL) cholesterol…
- Trial name
- PREMIER (NCT02347098)
- Testing
- intensive LDL-lowering therapy, standard statin monotherapy
- Where
- 4 sites in United States
- Volunteers
- 270 people
- Sponsor
- VA Office of Research and Development
Cardiac Amyloidosis
Analysis of the Evolution of SUVmax by Quantitative Analysis Method of Bisphosphonate Scintigraphy
Recently, treatment with tafamidis in patients with cardiac ATTR lead to a significant reduction in mortality. The Perugini score is commonly used on planar bone scans to differentiate cardiac ATTR from other amyloidosis or…
- Trial name
- QUANTI-SUV (NCT04849754)
- Testing
- bone scintigraphy
- Where
- France
- Volunteers
- 30 people
- Sponsor
- GCS Ramsay Santé pour l'Enseignement et la Recherche
Multiple Myeloma, Plasma Cell Neoplasm
Human Immune Globulin in Treating Patients With Primary Amyloidosis That is Causing Heart Dysfunction
RATIONALE: Antibodies, such as human immune globulin, can block the growth of abnormal cells in different ways. Some block the ability of abnormal cells to grow and spread.
- Trial name
- NCT00547365
- Testing
- Human immune globulin intravenous (IGIV)
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- University of Tennessee
Alpha-Thalassemia, Beta-Thalassemia
FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases
FLOWER is a completely virtual, nationwide, real-world observational study to collect, annotate, standardize, and report clinical data for rare diseases.
- Conditions
- Alpha-Thalassemia, Beta-Thalassemia, Amyloidosis, Amyotrophic Lateral Sclerosis
- Trial name
- NCT06539169
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- xCures
Transthyretin Amyloid Cardiopathy
ATTR-CM: A Multi-country, Non-interventional Disease Registry
This study is a multi-center, non-interventional, disease registry to characterize the natural history of ATTR-CM and treatment patterns in clinically diagnosed ATTR-CM patients.
- Trial name
- NCT06651073
- Testing
- Observational
- Where
- 17 sites in Hong Kong, Malaysia and 1 more
- Volunteers
- 350 people
- Sponsor
- Pfizer
Amyloidosis Cardiac
Ultrasound Therapy In Cardiac Amyloidosis
This is a prospective pilot clinical study of subjects with cardiac amyloidosis and control subjects without amyloidosis where we plan to evaluate changes in myocardial blood flow, systolic and diastolic function before and after…
- Trial name
- UTICA (NCT04667494)
- Testing
- Sonotherapy
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Cardiac Amyloidosis
Mitochondrial Function in Transthyretin Amyloidosis
Hereditary (familial) amyloidosis arising from the misfolding of a mutated or variant transthyretin, is the most frequent form of amyloid cardiomyopathy in the Caribbean basin.
- Trial name
- MIT-Amylose (NCT03328338)
- Where
- Martinique
- Volunteers
- 12 people
- Sponsor
- University Hospital Center of Martinique
Polyneuropathy, Amyloidosis
Prevalence of Wild-type TTR Cardiac Amyloidosis in Patients With Polyneuropathy of Unknown Cause.
To investigate to what extent chronic axonal length-dependent polyneuropathy (CAP) and/or small-fiber neuropathy (SFN) is part of early non-cardiac manifestations of wild-type TTR cardiac amyloidosis (wtTTR-CA).
- Trial name
- NCT05950867
- Testing
- ECG + echocardiography, Answering questionnaires
- Where
- Belgium
- Volunteers
- 150 people
- Sponsor
- Universitair Ziekenhuis Brussel
Cardiac Amyloidosis
Validation of Different Diagnostic Modalities in the Detection of Cardiac Amyloidosis Among Patients With "Red Flags"
The study aims to test and compare the diagnostic yield of different diagnostic modalities (speckle tracking echocardiography, CMR, serum and urine protein analysis and bone tracer scintigraphy) in the detection of cardiac…
- Trial name
- NCT06175858
- Testing
- CMR
- Volunteers
- 30 people
- Sponsor
- Assiut University
Transthyretin (TTR) Amyloid Cardiomyopathy
An Observational Study Using Artificial Intelligence (AI) Algorithms on Electrocardiography (ECG), Point-of-care Ultrasound (POCUS), and Transthoracic Echocardiophy (TTE) to Estimate the Under-diagnosis of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Across a Diverse Range of US Health Systems.
This is a multi-center, observational study with the overall objective to examine the scale of under-diagnosis for transthyretin amyloid cardiomyopathy (ATTR-CM) across a broad range of diverse health systems in the US using a…
- Trial name
- TRACE Network (NCT07062848)
- Testing
- AI Toolkit for ATTR-CM Diagnosis
- Where
- 12 sites in United States
- Volunteers
- 1,500,000 people
- Sponsor
- Yale University
Neuromuscular Disease, Neuromuscular Diseases (NMD)
A Phase 3 Study of NTLA-2001 in ATTRv-PN
This study will be conducted to evaluate the efficacy and safety of a single dose of nexiguran ziclumeran (NTLA-2001) compared to placebo in participants with ATTRv-PN.
- Conditions
- Neuromuscular Disease, Neuromuscular Diseases (NMD), Neurodegenerative Disease, Neurodegenerative Disease, Hereditary
- Trial name
- NCT06672237
- Testing
- nexiguran ziclumeran
- Where
- 14 sites in Argentina, Brazil and 4 more
- Volunteers
- 60 people
- Sponsor
- Intellia Therapeutics